Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependence
Lund, Sweden — 26 March 2021 — Camurus today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency’s (EMA) has issued a positive opinion recommending marketing authorization for a new, 160mg, monthly dose of Buvidal[®] (buprenorphine) prolonged release injection for the treatment opioid dependence in adults and adolescents from 16 years of age. “Today’s positive CHMP opinion marks an important step in providing people with opioid dependence in Europe access to a full range of Buvidal subcutaneous long-acting injections. Individualised